APA (7th ed.) Citation

DE, R., JC, H., MP, L., I, L., K, R., S, v. L., . . . MP, J. (2013). Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast cancer research and treatment, 139(1), 39. https://doi.org/10.1007/s10549-013-2529-7

Chicago Style (17th ed.) Citation

DE, Ramirez-Ardila, et al. "Hotspot Mutations in PIK3CA Associate with First-line Treatment Outcome for Aromatase Inhibitors but Not for Tamoxifen." Breast Cancer Research and Treatment 139, no. 1 (2013): 39. https://doi.org/10.1007/s10549-013-2529-7.

MLA (9th ed.) Citation

DE, Ramirez-Ardila, et al. "Hotspot Mutations in PIK3CA Associate with First-line Treatment Outcome for Aromatase Inhibitors but Not for Tamoxifen." Breast Cancer Research and Treatment, vol. 139, no. 1, 2013, p. 39, https://doi.org/10.1007/s10549-013-2529-7.